HK1115192A1 - Methods and compositions for diagnosis and treatment of influenza - Google Patents

Methods and compositions for diagnosis and treatment of influenza

Info

Publication number
HK1115192A1
HK1115192A1 HK08111006.1A HK08111006A HK1115192A1 HK 1115192 A1 HK1115192 A1 HK 1115192A1 HK 08111006 A HK08111006 A HK 08111006A HK 1115192 A1 HK1115192 A1 HK 1115192A1
Authority
HK
Hong Kong
Prior art keywords
pdz
influenza
methods
compositions
influenza virus
Prior art date
Application number
HK08111006.1A
Other languages
English (en)
Inventor
Peter S Lu
Joshua D Rabinowitz
Michael P Belmares
Original Assignee
Arbor Vita Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbor Vita Corp filed Critical Arbor Vita Corp
Publication of HK1115192A1 publication Critical patent/HK1115192A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK08111006.1A 2005-07-01 2008-10-02 Methods and compositions for diagnosis and treatment of influenza HK1115192A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US69622105P 2005-07-01 2005-07-01
US72637705P 2005-10-13 2005-10-13
US76529206P 2006-02-02 2006-02-02
US79227406P 2006-04-14 2006-04-14
PCT/US2006/026155 WO2007018843A2 (fr) 2005-07-01 2006-07-03 Methodes et compositions de diagnostic et de traitement de la grippe

Publications (1)

Publication Number Publication Date
HK1115192A1 true HK1115192A1 (en) 2008-11-21

Family

ID=37307088

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08111006.1A HK1115192A1 (en) 2005-07-01 2008-10-02 Methods and compositions for diagnosis and treatment of influenza

Country Status (9)

Country Link
US (2) US7595151B2 (fr)
EP (1) EP1910837B1 (fr)
JP (1) JP2009500611A (fr)
AT (1) ATE549624T1 (fr)
AU (1) AU2006276813A1 (fr)
CA (1) CA2613482A1 (fr)
HK (1) HK1115192A1 (fr)
IL (1) IL188460A (fr)
WO (1) WO2007018843A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7595152B2 (en) * 2005-07-01 2009-09-29 Arbor Vita Corporation Detection of influenza virus
CA2613482A1 (fr) * 2005-07-01 2007-02-15 Arbor Vita Corporation Methodes et compositions de diagnostic et de traitement de la grippe
WO2008048276A1 (fr) * 2006-10-21 2008-04-24 Arbor Vita Corporation Détection du virus de la grippe de type B
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
WO2007098184A2 (fr) * 2006-02-21 2007-08-30 Nanogen, Inc. Méthodes et compositions pour détection d'analytes
KR101747665B1 (ko) * 2007-07-17 2017-06-15 소마로직, 인크. 시료의 다중분석
US9212205B2 (en) 2007-07-26 2015-12-15 University Of Rochester Nucleic acid binding compounds and methods of use
WO2009117362A1 (fr) * 2008-03-15 2009-09-24 Arbor Vita Corporation Diagnostics ns1-np d’une infection par le virus de la grippe
CN101649356B (zh) * 2009-07-24 2012-09-05 浙江省疾病预防控制中心 甲型h1n1流感病毒荧光定量检测试剂盒及检测方法
KR101341640B1 (ko) * 2010-02-05 2013-12-16 한국전자통신연구원 단백질 미세 구조 분석 방법 및 단백질 미세 구조 분석용 어레이
WO2011146825A2 (fr) * 2010-05-20 2011-11-24 The Board Of Trustees Of The University Of Arkansas Aptamères spécifiques de la grippe aviaire h5n1 et leur utilisation
WO2013025525A1 (fr) * 2011-08-12 2013-02-21 The Board Of Trustees Of The Leland Stanford Junior University Compositions et procédés pour la régulation spécifique de la pyruvate déshydrogénase kinase
US9416391B2 (en) 2011-11-18 2016-08-16 Thelial Technologies S.A. Method for identifying cancer drug candidates in Drosophila
US9428550B2 (en) 2012-01-18 2016-08-30 Governing Council Of The University Of Toronto Peptides and methods and uses thereof for preventing retinal disorders
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
KR101471245B1 (ko) * 2012-05-31 2014-12-10 충북대학교 산학협력단 Ａ형 인플루엔자 바이러스 감염 질환의 예방 및 치료용 조성물
US9493542B2 (en) * 2013-02-22 2016-11-15 Augusta University Research Institute, Inc. Methods of using ERBB2 conjugate peptides
US20140329706A1 (en) * 2013-05-01 2014-11-06 California Institute Of Technology Affinity tags, and related affinity ligands, engineered proteins, modified supports, compositions, methods and systems
JP2018128408A (ja) * 2017-02-10 2018-08-16 東ソー株式会社 抗体凝集体形成予測方法
US11549114B2 (en) * 2020-03-27 2023-01-10 Apollo Biomedical, LLC Multiple rapid detection kits and methods for various viruses
WO2021188580A1 (fr) * 2020-03-17 2021-09-23 Detect, Inc. Test de diagnostic rapide
CN111410694B (zh) * 2020-03-27 2020-12-22 浙江省人民医院 一种抗胶质瘤的多肽分子及其应用
US11493514B2 (en) * 2020-07-20 2022-11-08 United Arab Emirates University Method and system for virus and protein-antibody interactions detection and monitoring based on optical light intensity and electrical parameters

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO870613L (no) 1986-03-05 1987-09-07 Molecular Diagnostics Inc Deteksjon av mikroorganismer i en prŸve inneholdende nukleinsyre.
AU620330B2 (en) 1987-05-29 1992-02-20 Smithkline Beckman Corporation Immunodiagnostic assays using chimeric antigens
ATE173508T1 (de) 1988-05-20 1998-12-15 Hoffmann La Roche Befestigung von sequenzspezifischen proben
US5856092A (en) 1989-02-13 1999-01-05 Geneco Pty Ltd Detection of a nucleic acid sequence or a change therein
ATE160818T1 (de) 1990-06-01 1997-12-15 Chiron Corp Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit
US5846710A (en) 1990-11-02 1998-12-08 St. Louis University Method for the detection of genetic diseases and gene sequence variations by single nucleotide primer extension
US5888819A (en) 1991-03-05 1999-03-30 Molecular Tool, Inc. Method for determining nucleotide identity through primer extension
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
GB9502489D0 (en) * 1995-02-09 1995-03-29 Animal Health Trust Expression of the non-structural protein NS1 of influenza virus and detection of anti-NS1 antibody in serum
AU2001277986A1 (en) * 2000-07-25 2002-02-05 Axcell Biosciences Corporation Identification and isolation of novel polypeptides having pdz domains and methods of using same
US7312041B2 (en) * 2001-02-16 2007-12-25 Arbor Vita Corporation Methods of diagnosing cervical cancer
JP4426122B2 (ja) * 2001-01-23 2010-03-03 株式会社ビーエル 血中抗原検出方法及び装置
US20030119203A1 (en) * 2001-12-24 2003-06-26 Kimberly-Clark Worldwide, Inc. Lateral flow assay devices and methods for conducting assays
CA2495449A1 (fr) 2002-09-09 2004-03-18 Arbor Vita Corporation Procede de diagnostic du cancer du col de l'uterus
JP2004161685A (ja) * 2002-11-14 2004-06-10 Bl:Kk 卵黄関連蛋白およびその用途
JP2004166564A (ja) * 2002-11-19 2004-06-17 Bl:Kk モノクローナル抗体および結核症診断法
JP4933258B2 (ja) * 2003-09-22 2012-05-16 クイデル コーポレーション 試料中の複数分析物の検出装置
JP2006067979A (ja) * 2004-09-06 2006-03-16 Bl:Kk インフルエンザａ型ウイルスの免疫検出法
CA2613482A1 (fr) * 2005-07-01 2007-02-15 Arbor Vita Corporation Methodes et compositions de diagnostic et de traitement de la grippe
US7595152B2 (en) * 2005-07-01 2009-09-29 Arbor Vita Corporation Detection of influenza virus
US7946135B2 (en) * 2007-01-02 2011-05-24 Draka Comteq, B.V. Extended-baking process for glass deposition tubes

Also Published As

Publication number Publication date
ATE549624T1 (de) 2012-03-15
US20100112547A1 (en) 2010-05-06
WO2007018843A2 (fr) 2007-02-15
EP1910837B1 (fr) 2012-03-14
AU2006276813A1 (en) 2007-02-15
IL188460A (en) 2012-02-29
WO2007018843A3 (fr) 2007-06-28
CA2613482A1 (fr) 2007-02-15
IL188460A0 (en) 2008-04-13
US20070161078A1 (en) 2007-07-12
EP1910837A2 (fr) 2008-04-16
US7595151B2 (en) 2009-09-29
JP2009500611A (ja) 2009-01-08

Similar Documents

Publication Publication Date Title
HK1115192A1 (en) Methods and compositions for diagnosis and treatment of influenza
WO2007098184A3 (fr) Méthodes et compositions pour détection d'analytes
WO2009151628A3 (fr) Surveillance de tcr-b en vue de déterminer une thérapie de vih et l'évolution d'une maladie
NZ602056A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2007062090A3 (fr) Procedes et compositions lies a des analyses de lymphocytes b
WO2006124641A3 (fr) Anticorps diriges contre la mesotheline utiles pour des dosages immunologiques
EA201992748A1 (ru) Диагностические анализы для обнаружения, количественного определения и/или отслеживания микроорганизмов и других аналитов
EP2394163A4 (fr) Procédés pour détecter le polyomavirus jc
WO2007005948A3 (fr) Methodes et compositions de diagnostic et de traitement d'infections virales et bacteriennes
TW200741203A (en) Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
TW200639404A (en) Method of assessing the effectiveness of a treatment regimen
BRPI0407299A (pt) Métodos para detectar um analito associado com o hiv, para determinar a relação de células t cd4+ para células t cd8+, e para detectar rna do hiv, em uma amostra de sangue
EA201390638A1 (ru) Обогащение и идентификация фетальных клеток в материнской крови и лиганды для такого применения
WO2009105212A3 (fr) Détection de polyomavirus
NZ609824A (en) Immunochromatography devices, methods and kits
WO2009007846A3 (fr) Procédé pour modifier, isoler, détecter, visualiser et quantifier des peptides, polypeptides et protéines contenant de la citrulline et/ou de l'homocitrulline
WO2010051544A3 (fr) Plateforme de diagnostic rapide homogène basée sur le transfert d'énergie par résonance de fluorescence des lanthanides
WO2009023331A3 (fr) Anticorps et procédés améliorés de manipulation d'un échantillon test destinés à être utilisés dans des dosages pour myélopéroxidase
MX2009010751A (es) Composiciones y metodos de deteccion.
WO2012103337A3 (fr) Dosages et procédé de séquençage de microbes directement à partir de complexes immuns
WO2006110748A3 (fr) Gene de reponse au complement 32 (rgc-32) lors d'une maladie
WO2006053251A3 (fr) Methode permettant de mesurer des peptides beta-amyloides
WO2007037910A3 (fr) Elimination specifique de cellules immunitaires activees
UA94945C2 (ru) Способ выделения и определения вирусной нагрузки в образце панкреатина
WO2011109112A3 (fr) Procédé de détection de la protéine tau et des fragments de tau dans le sérum

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180703